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Abstract 
Clinical evidence reveals the existence of a trauma induced secondary cardiac injury 
(TISCI) which is associated with poor patient outcomes.  The mechanisms leading to 
TISCI in injured patients are uncertain.  Conversely, animal models of trauma 
haemorrhage have repeatedly demonstrated significant cardiac dysfunction following 
injury, and highlighted mechanisms through which this might occur.  The aim of this 
review was to provide an overview of the animal studies describing TISCI and its 
pathophysiology.  
Basic science models of trauma show evidence of innate immune system activation via 
Toll-Iike receptors (TLRs), the exact protagonists of which remain unclear.  Shortly 
following trauma and haemorrhage, cardiomyocytes upregulate gene regulatory protein 
and inflammatory molecule expression including Nuclear factor kappa beta (NF-κB), 
tumour necrosis factor alpha (TNFα) and interleukin-6 (IL-6).  This is associated with 
expression of membrane bound adhesion molecules and chemokines leading to marked 
myocardial leukocyte infiltration.  This cell activation and infiltration is linked to a rise in 
enzymes that cause oxidative and nitrative stress and subsequent protein misfolding 
within cardiomyocytes.  Such protein damage may lead to reduced contractility and 
myocyte apoptosis.  Other molecules have been identified as cardioprotective following 
injury.  These include p38 mitogen-activated protein kinases (MAPK) and heat shock 
proteins.   
The balance between increasing damaging mediators and a reduction in cardio-
protective molecules appears to define myocardial function following trauma.  
Exogenous therapeutics have been trialled in rodents with promising abilities to 
favourably alter this balance, and subsequently lead to improved cardiac function.  
 
 3 
Keywords  
Trauma, Secondary, Dysfunction, Cardiac, Mechanisms, Inflammation 
  
 4 
Trauma Induced Secondary Cardiac Injury in Patients 
There is mounting evidence to support the existence of a trauma induced secondary 
cardiac injury (TISCI), namely the development of cardiac injury and dysfunction in the 
absence of direct trauma to the heart (1-8).  TISCI has been shown to occur acutely in at 
least ten percent of trauma patients, and is associated with adverse outcomes, including 
an increased risk of death (1, 2, 9). 
Many studies have demonstrated a significant risk of adverse cardiac events (ACEs) 
following trauma that bear no association to the presence or severity of chest injury.  In 
a retrospective review of over a million injured patients, the risk of post-traumatic 
myocardial infarction (MI) was found to nearly double (4).  Of some 1,051,081 injury 
discharges, 32,616 (3.10%) acute MIs were diagnosed.  The study revealed that 
abdominal or pelvic trauma led to a 65% (Odds Ratio [OR] 1.65, 95% Confidence Intervals 
[95% CI] 1.26-2.16) increase in the risk of acute MI in patients below the age of 46 years, 
regardless of confounders or coronary artery status.  In patients over 46 years, abdominal 
or pelvic trauma alone nearly doubled the risk of acute MI (OR 1.93, 95% CI 1.42-2.62).  
When confirmed by coronary angiography (CA), the risk of MI was six times greater (OR 
6.33, 95% CI 4.00-9.99). 
Atrial arrhythmias have also been reported in trauma patients, and associated with 
increasing age, catecholamine use, the presence of a systemic inflammatory response 
(SIRS) and overall injury severity.  Importantly, the presence of arrhythmias may be 
associated with a longer length of critical care stay and linked to higher mortality (10, 
11).  
Cardiac failure in severely injured patients has been observed at an average onset of two 
days following injury (12).  When myocardial contractile dysfunction following trauma is 
identified with invasive monitoring, it may be treated effectively with inotropic support 
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(13).  Decreased cardiac index (CI) following trauma is related to increased mortality, and 
conversely a higher CI with survival (14, 15).  
In addition to adverse cardiac events, heart specific biomarkers have identified both the 
severity and clinical significance of secondary cardiac injury.  Troponin I rises after 
trauma and may be associated with both an increased risk of ACEs and death (1, 5, 6).  In 
Martin et al’s (6) study of over a thousand critically injured patients, around a third of the 
cohort (29%) demonstrated a rise in Troponin I.  When adjusted for, only the severity of 
injury, base excess and degree of physiological derangement were predictors of Troponin 
I increase.  Neither the presence nor severity of thoracic injury, however, was associated 
with Troponin I.  Elevated Troponin I levels were also a significant predictor of mortality 
(OR 2.1, 95% CI 1.4–3.1).  Fifty patients (4.6%) had an ACE of some description and these 
were associated with increases in Troponin I.  Beta blockers were linked to survival and 
a 50% decrease in mortality was seen in patients with Troponin I increases on these 
medications. 
Furthermore, B-type natriuretic peptide (BNP) may be elevated in the absence of 
echocardiographic evidence of congestive heart failure (8, 16).  Measured 24 hours after 
injury, levels of NT-proBNP correlate with a decreased CI and multiple organ dysfunction 
syndrome (MODS) (7, 8).  Moreover, in 135 critically injured patients, BNP levels were 
found to be significantly higher in non-survivors compared to survivors in blood taken 
on admission, and again after 24 and 72 hours post admission (1). Elevations in heart 
specific fatty acid binding protein (H-FABP) over the same time frames were also 
associated with subsequent ACEs (1, 3).  
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Echocardiographic abnormalities, including regional wall abnormalities and reduced 
ejection fraction, have been shown in patients following isolated traumatic brain injury 
(TBI) (17).  Cardiac dysfunction in TBI is again linked to raised plasma Troponin and 
mortality (8, 18).  
Post-mortem studies have corroborated the existence of TISCI.  A review of 125 trauma 
patients undergoing autopsy revealed lesions in 20% of the hearts examined.  Lesions 
were apparent as early as four hours after injury, and typically located around the left 
ventricle.  Histological changes included subendocardial haemorrhages, interstitial 
oedema, mononuclear infiltration, coagulative necrosis and evidence of hypoxic injury in 
the absence of existing coronary disease (19).  An older post-mortem study of homicide 
trauma victims has supported these findings, and revealed myofibrillar degeneration, 
namely scattered clusters of myocytes with homogeneous eosinophilic transverse bands 
alternating with areas of fine granulation (20).  Contraction bands were also observed, a 
process whereby hypercontraction (secondary to catecholamine surges) of the cardiac 
muscle leads to structureless masses of contractile protein.  Accordingly, the data 
presented provided good evidence of TISCI, and suggested that such heart damage is the 
result of the cardiotoxic effect of catecholamines. 
In spite of the clinical evidence revealing the presence and impact of TISCI, few patient 
studies have explored and verified the cause of this secondary cardiac injury.  In contrast, 
animal models have repeatedly verified the deleterious effects of trauma and 
haemorrhage on the heart, and explored the mechanisms through which this injury may 
occur.  The bulk of these studies implicate inflammation, often revealing that blocking the 
inflammatory process leads to an improvement in cardiac function.  
The aim of this review was to provide an overview of the mechanisms involved in cardiac 
injury and dysfunction studied in animal models of trauma and haemorrhage.  
 7 
Animal Trauma Models and Impaired Myocardial Physiology  
Rodent models have consistently demonstrated cardiac dysfunction following trauma, 
haemorrhagic shock (H-S) and trauma-haemorrhage (T-H).  Isolated trauma-induced 
cardiac injury, without blood loss, has been assessed in a minority of studies, and the 
impact of injury generally determined in terms of cardiomyocyte apoptosis and 
autophagy (Table 1).  Isolated trauma is conducted using the Noble Collip drum, a 
technique where the rodent is placed inside a rotating drum and exposed to a pre-
determined number of revolutions.  They do not sustain life threatening trauma but 
instead a significant amount of soft tissue injury.   
Haemorrhage alone has also been relatively less investigated, and research focused 
predominantly on the role of inflammation (Table 2.) 
Conversely, models of combined T-H are extensively described in the literature, and 
report a variety of mechanisms leading to the development of secondary cardiac injury 
and dysfunction, with inflammation again frequently investigated (Table 3).  
Both in vivo and ex vivo models have been reported in the literature, and used a number 
of invasive and non-invasive haemodynamic monitoring to diagnose cardiac dysfunction 
(21-69), including the use of LV micro-manometry (66).  In studies where the impact of 
trauma and haemorrhage is investigated, injury was most commonly a laparotomy.  
Performing a laparotomy alone means that the animals can be recovered after surgery 
and cardiac dysfunction can be assessed at a later stage.  However, one potential 
drawback of this approach is that it can limit the severity of the insult, and therefore the 
translational potential when considering severely injured polytrauma patients.   
The majority of the studies reviewed included a resuscitation phase in the study protocol. 
The administration of fluid after an antecedent period of hypotension, is not only 
important to allow animals to survive through a longer experimental phase, but also 
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allows for the development of reperfusion-related phenomenon in tissues previously 
subjected to a period of ischaemia.  The inclusion of a resuscitation phase adds another 
level of complexity to these challenging small animal models, but is important in order to 
simulate the complex pathophysiology associated with ischaemia-reperfusion related 
inflammation and injury within the myocardium.  Resuscitation protocols within the 
literature vary in terms of volume and nature of the fluid given.  The majority of the 
models in the literature implemented a fixed-volume resuscitation strategy (based upon 
the volume of blood loss) with crystalloid solutions (70), rather than whole blood (31), 
or a combination of blood and crystalloid.  One study adopted a targeted resuscitation 
approach, with intravenous fluid given in accordance with mean arterial pressure (53).   
Complex in vivo studies have provided important insights into key effector molecules and 
mechanisms involved in the development of myocardial dysfunction.  The role of sex 
hormones in rat models in particular have been widely reported, and manipulation of 
these pathways has been invaluable in characterising the cardio-protective effect of 
oestrogens.  Genetically-modified mice have been used to investigate the contribution of 
inflammatory signalling pathways modulated by the Toll-like receptors (TLRs) (27, 28). 
Cardiac dysfunction has manifested through a number of parameters including a decline 
in stroke volume (SV), or a reduction in either the maximum rates of rise and fall of 
ventricular pressure (-dP/dtmax, 34), left ventricular developed pressure (LVDP, 25) and 
ventricular peak systolic pressure, cardiac output (CO, 70) and CI (59).  Research reveals 
cardiac impairment occurs both during systole and diastole, and electrophysiological and 
significant conduction abnormalities have been reported (31, 53).  Cardiac dysfunction 
leads to a rise in plasma lactate levels, which reverse if myocardial function is restored 
(35).  Elevations in cardiac-specific biomarkers such as troponin and creatine kinase in 
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response to trauma have also been reported.  Indeed, these biomarkers may rise as early 
as two hours after injury (23).  
In terms of timings, limited research has documented a significant, hyper-acute (<1 hour) 
reduction in cardiac function following trauma.  Impaired contractility in cardiomyocytes 
has been demonstrated as early as 30 minutes after trauma without haemorrhage, 
perhaps suggesting that hyper-acute dysfunction is not necessarily dependent upon the 
combination of shock with injury (23).  Overall, however, the onset of myocardial 
depression is usually between two and five hours following injury (33, 58).  Later onset, 
namely up to 24 hours has been recorded (24).  
Hearts excised from rats 24 hours following T-H demonstrated impaired cardiac function 
independent of coronary perfusion and calcium ion concentration (31).  The decline in 
cardiac function following T-H does not reverse with fluid resuscitation and increased 
preload suggesting impaired myocardial contractility (53). 
Studies have demonstrated the development of cardiac injury with biomarker rise, 
inflammation with local and systemic inflammatory cytokine release, and have 
characterised the nature of resultant myocardial dysfunction both in vivo and ex vivo and 
in isolated cardiomyocytes (23).  Animal studies have also been used to assess potential 
cardio-protective pathways and molecules.  Modulation of apoptotic and inflammatory 
pathways and effectors such as IL-6 and TNF-α, have been identified as being protective.  
Pre-induction of heat shock proteins was found to confer benefit in terms of subsequent 
cardiac performance (41), but the majority of studies assessed potential therapeutics 
delivered agents during a resuscitation phase.  
Sensing Injury and the Role of the Innate Immune System 
TLRs are central to the innate immune system and expressed on both immune and non-
immune cells including cardiomyocytes (71, 72).  TLRs respond to pathogen associated 
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molecular patterns (PAMPs) and endogenous Damage Associated Molecular Patterns 
(DAMPs) released during cellular stress (73).  TLR activation represents a mechanism of 
cardiomyocyte traumatic injury recognition and subsequent activation of an innate 
immune response. 
Trauma causes soft tissue injury and cellular damage leading to release of DAMPs, 
thereby activating TLRs independent of exogenous pathogen involvement, so called 
‘sterile inflammation’ (Figure1 )(74).  TLR4 is unregulated following injury and is likely 
to play a crucial role in the subsequent cardiac dysfunction by sensing tissue damage and 
activating cardiomyocyte inflammatory pathways (75).  T-H induced cardiac dysfunction 
is dependent on TLR4 as shown by significant reduction in dysfunction with TLR4 gene 
knock-out rodents, and when using TLR4 antagonists (27, 58).  Ameliorating the TLR4 
response following injury led to reduced cardiac activity of the transcription factor 
nuclear factor kappa beta (NF- κB) and reduced cytokine production (27).  TLR9 has also 
been studied following T-H and a reduction in cardiac dysfunction following TLR9 ligand 
binding has been shown (28). 
Hearts and cardiomyocytes exposed to lymph from T-H exposed animals demonstrated 
an initial dose dependent inotropic effect immediately after exposure, which was 
followed by progressive loss of contractile function (31).  A recent study revealed a 
reduction in cardiac contractile dysfunction following H-S in animals subject to 
mesenteric lymph drainage (65).  The lymph studied was sterile and contained similar 
levels of cytokines when compared to lymph from control animals, thereby suggesting a 
role for ALARMIN and DAMP type molecules in the process (31, 32). 
Cardiomyocyte Amplification of the Immune Response to Injury 
Following T-H, trauma and isolated haemorrhage in animal models, there are rises in 
plasma and cardiomyocyte tumour necrosis factor alpha (TNFα, 21, 22) and interleukin 
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6 (IL-6, 33, 35) levels which are repeatedly associated with cardiac dysfunction.  
Reductions in TNFα (23) and IL-6 (76) are conversely linked to improved cardiac 
function. 
Cardiomyocytes exhibit intrinsic leukocyte-like function as demonstrated by significant 
gene expression of TNFα and IL-6 messenger ribonucleic acid (mRNA) in cardiomyocytes 
following T-H (33, 36, 77).  Myocardial TNFα production begins as early as 30 minutes 
following injury (53).  Increased IL-6 expression following trauma is linked to a rise in 
the stress associated transcription factor hypoxia-inducible factor-1α (HIF-1α) (78).  
The transcription factor NF-κB is present in cell cytoplasm bound to the protein 
inhibitory kappa B (IκB).  Following T-H there is an early cytokine dependent rise in NF-
κB activity with an increase in cardiomyocyte IκB-alpha phosphorylation, NF-κB 
transcription factor and both nuclear levels of NF-κB and NF-κB DNA-binding activity 
(57).  This is associated with a decline in myocardial contractility and cardiac output (35).  
Attenuation of the NF-κB pathway leads to a reduction in IκB-alpha phosphorylation, NF-
κB expression and activity and a reduction in cardiomyocyte TNFα, IL-6 and leukocyte 
adhesion molecule production (36).  
Cardiomyocyte activation following trauma leads to a cytokine dependent rise in cardiac 
adhesion molecules, including intracellular adhesion molecule-1 (ICAM-1), cytokine 
induced chemoattractant-1 (CINC-1) and CINC-3 (29, 35).  Consequently, a marked 
increase in cardiac tissue neutrophil infiltration may occur as early as two hours 
following injury with a subsequent decline in contractile function (30, 36, 64).  
Pharmacological reduction in expression of the chemoattractants, adhesion molecules 
and subsequent reduced neutrophil infiltration have been associated with preservation 
of cardiac output after T-H (26, 44, 48). 
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Following innate immune sensing of injury, cardiomyocytes intrinsically amplify the 
inflammatory response with marked expression of cytokines and adhesion molecules 
leading to neutrophil infiltration. 
Cardiomyocytes Stressors  
The rise in myocardial cytokines, chemoattractant and adhesion molecules and 
leukocytes leads to an increase in myocardial enzymes capable of producing oxygen and 
nitrogenous radicals (25).  These include Myeloperoxidase (MPO), Nicotinamide Adenine 
Dinucleotide Phosphate-oxidase (NADPH) and inducible nitric oxide synthase (iNOS) (22, 
35, 61).  
Cardiac MPO levels rise shortly following injury.  MPO is stored in neutrophil 
granulocytes and catalyses the formation of volatile reactive oxidative and nitrating 
substances which are thought to contribute to cardiomyocyte protein misfolding and 
damage with subsequent reduced contractility (44, 48, 66).  
iNOS is found in leukocytes, endothelial cells and cardiomyocytes and its expression and 
activation is dependent on stress and cytokine induced activation prior to producing 
significant quantities of Nitric Oxide (NO) (79).  Increased cardiac iNOS expression has 
been shown five hours after tissue injury (80) and associated with increased NO content 
and cardiac tissue peroxynitrite formation.  This is a marker of nitrative stress and linked 
to impaired left ventricle developed pressure and cardiac function (25, 26).  The increase 
in NO, superoxide production and protein nitrotyrosine levels can be blocked by iNOS 
inhibition, leading to preservation of cardiac function (21). 
Cardiomyocyte Apoptosis 
The rise in myocardial oxidative and nitrative radicals following injury leads to a protein 
misfolding and DNA damaging milieu which in turn activates apoptotic machinery within 
cardiomyocytes.  A rise in myocardial Caspase-3 activity and TUNEL-positive cells has 
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been demonstrated six hours after trauma, peaking at 12 hours, but ongoing at 24 hours.  
This caspase dependent dysfunction was associated with reduced CO.  This was 
significantly attenuated by Caspase inhibition or pharmacological inhibition of pro-
apoptotic factors and preservation of anti-apoptotic proteins (64, 81).  There was no 
concurrent and significant increase in plasma Troponin levels, suggesting cardiac 
depression was not due to necrosis.  A rise in caspase-3 activation has been shown in 
cardiomyocytes exposed to plasma from injured animals but not from control animals, 
implicating dependence on plasma circulated mediators (22).  Increases in other pro-
apoptotic protein expression has been observed following T-H, including bcl-2-like 
protein 4 (bax) (64).  Furthermore, T-H is associated with a decrease in anti-apoptotic 
factors such as protein B-cell lymphoma 2 (bcl-2) (64).  The activation of apoptosis is 
cytokine, oxidative and nitrative stress dependent (66, 82).  
Cardiomyocyte Protectors 
The mediators discussed thus far are upregulated by injury with resultant myocardial 
damage.  There are, however, mediators which offer myocardial protection.  Following 
injury, these can become depleted or downregulated, and the resultant imbalance 
between cardiac stressors and cardiac protectors is an important component in trauma 
induced secondary cardiac injury and dysfunction (Figure 2).  
There is a significant decrease in the function of the cell signalling mediators Akt and p38 
mitogen-activated protein kinase (MAPK) in the myocardium following T-H as 
demonstrated by a reduction in phosphorylated cardiac Akt and p38 MAPK (45, 48).  This 
is thought to lead to myocardial dysfunction due to increased leukocyte infiltration and 
cardiomyocyte apoptosis.  Indeed, the rise in cardiac inflammatory molecules following 
T-H can be abolished by the administration of exogenous substances that prevent 
reduction in pAkt, such as Oestrogen (38, 44, 83) and Tropisetron (30).  Preservation of 
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cardiac pAkt is then linked to reduced neutrophil infiltration, apoptosis and restoration 
of cardiac glycogen levels with subsequent attenuation in cardiac contractile dysfunction 
(84).  Similarly maintaining cardiac phosphorylated p38 MAPK levels is associated with 
preservation of cardiac function following T-H (29).  Conversely, p38 MAPK has been 
shown to play a contributory role to myocardial inflammation following haemorrhage 
with inhibition of p38 MAPK phosphorylation associated with reduced cytokine 
production and dysfunction (77).  
Heat shock proteins (HSPs) minimise damage caused to cells from stressors such as heat, 
hypoxia and ischaemia (85).  Induction of HSPs is controlled by transcription factors 
called heat-shock factors (HSFs).  T-H is associated with an increase in cardiac haem 
oxygenase 1 (HO-1, HSP-32) and a reduction in HSP-60 (49) and HSP-90 (86). 
Pharmacological preservation of myocardial levels of HSP-60 and HSP-90 and increased 
levels of HSF-1, H0-1, HSP-70 (87), HSP-27 and the HSP -crystallin concentration 
expression following T-H lead to a reduction in cardiac cytokine concentration and 
improved cardiac function following injury (38, 44, 79). 
Female rats in the pro-oestrus phase have the highest oestrogen level and demonstrate a 
significant degree of cardio-protection following injury (34).  There is a decrease in 
oestrogen receptor (OR) expression in cardiomyocytes following T-H, and preservation 
of these receptors by increased exogenous or endogenous oestrogen and testosterone 
antagonists is again associated with improved cardiac output (88-90).  Furthermore, this 
reduction in ORb expression is associated with a rise in cardiac TNFα, IL1-6, chemokines 
and adhesion molecules (29, 34, 40).  Oestrogen mediated cardio-protection is also 
dependent on Akt and MAPK (29, 42, 45).  
T-H induced rises in cardiac TNFα, MIP-2, CINC-1, ICAM-1 and MPO are abolished by 
administering exogenous oestrogen (29, 44).  ORs are classically considered to initiate 
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the activity of a downstream intra-nuclear ligand dependent transcription factor. 
However, due to the rapid speed of onset and inability of transcription inhibitors to 
negate the effects of OR agonists, additional oestrogenic effects are thought to occur 
independent of gene up-regulation (90).  
Limitations in Applying the Basic Science to the Clinical Context  
There are restrictions to the experimental studies, however, which limit both their 
applicability and their relevance to the clinical setting.  Experiments are designed to 
create damage to the heart using scenarios that are not usually reflective of clinical 
patterns of injury.  In trauma-haemorrhage (T-H) models, injury often takes the form of 
laparotomy, with the Noble-Collip drum used as an alternative in models of isolated 
injury in the absence of haemorrhage (22-26).  H-S is performed in a pressure-dependent 
or volume-dependent fashion with controlled blood withdrawal (33-35).  In the majority 
of haemorrhage and T-H models, animals undergo resuscitation (53, 62), though some 
haemorrhage models are non-resuscitated (58).  It is therefore difficult to apply these 
uniform models to heterogeneous trauma populations, who present with a wide variety 
of injuries and a broad spectrum of physiological derangement.  Much of the clinical 
evidence is from retrospective cohort studies, and primarily limited to small numbers of 
critically injured patients only.  Clinical manifestations of secondary cardiac injury are 
restricted to isolated diagnoses, whilst biomarker studies have investigated single 
markers.  There exists some further difficulty, therefore, in translating the findings of 
interventional animal experiments to the observational research which forms the bulk of 
the current clinical evidence. 
Furthermore, the animals are not exposed to the same degree and nature of interventions 
as trauma patients are such as medications, blood products, multiple operations and 
superimposed factors such as infection.   
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The effects these have on the human heart are therefore inevitably neglected.   
Animals typically do not suffer co-morbidity or poor background physiology, due to 
advanced age or smoking for example.  This further limits the applicability of the 
experimental evidence to the clinical context and highlights the need for more patient 
based research.   
However, the animal models have been invaluable in demonstrating cardiomyocyte 
damage and myocardial dysfunction following trauma. They have provided important 
insights into the key molecular pathways of cardiac pathophysiology in the context of the 
complex, multi-factorial scenario of sterile inflammation resulting from injury combined 
with haemorrhagic shock.    Research has identified novel therapeutic strategies including 
the administration of sex hormones, anti-inflammatory and antibody blocking agents 
capable of damping down the inflammatory drive behind cardiac injury and dysfunction.  
The greater understanding of these processes has provided platforms on which to base 
future clinical studies.  
Future Directions 
There is an urgent need to develop treatment strategies which will not only prevent acute 
cardiovascular collapse, but also ameliorate cellular injury and prevent the cardiac 
dysfunction seen after resuscitation.  The focus should now shift toward taking promising 
therapeutic studies into the clinical setting with well-designed translational studies.  This 
field of trauma research offers an exciting opportunity for clinical and pre-clinical 
researchers to collaborate with the aim of developing translatable models in which to 
investigate new therapeutics.   
Injury and surgery has been shown to be associated with the formation of neutrophil 
extracellular traps (NETs) (91).  It is thought that NET formation represents an innate 
immune system response, which, via inflammatory pathways has a detrimental impact 
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upon organ function after trauma (92).  The role of this NET formation and their 
subsequent release of inflammatory mediators upon cardiomyocytes and cardiac 
function after trauma has yet to be determined, and further work in this area is therefore 
required.  
There are a number of highly sophisticated, clinically relevant imaging technologies, 
which could also be applied in this area.  Non-invasive imaging technologies are 
developing which have applications in pre-clinical trauma research.  Micro-imaging 
modalities such as echocardiography and magnetic resonance, for example, are available 
with improved resolution, which would allow for detailed in vivo assessment of rodent 
hearts under conditions of trauma-haemorrhage.  Application of these imaging 
techniques would be of benefit in mechanistic studies and in monitoring responses to 
therapeutics.  
As we regard technological advancement in cardiovascular research to apply to these 
studies, we should also take opportunities arising from advances from other areas of 
resuscitation research.  For example, the development of selective aortic arch perfusion 
(SAAP) methods may represent, in the future, a targeted way of delivering cardio-
protective drugs directly to the coronary circulation.  
Building upon the existing knowledge gained from animal models of cardiac injury and 
dysfunction and developing future models in this way will optimise translational 
potential, and allow effective cardio-protective interventions identified in the laboratory 
to be assessed in the clinical setting.  Ultimately, such research will be directed at further 
reducing the burden of injury, both in terms of the mortality and morbidity associated 
with trauma induced secondary cardiac dysfunction.  
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Conclusion 
Clinical studies of injured patients reveal a secondary cardiac injury and dysfunction 
associated with poorer outcomes.  Animal models of trauma have repeatedly 
demonstrated this entity, and revealed many of the mechanisms that lead to it.  
Substances with therapeutic promise in animal models either reduce damaging 
molecules, or prevent reduction in protective agents, or both.  Further clinical evidence 
should substantiate the findings of the pre-clinical experiments.  In turn, this could lead 
to improved survival and function after trauma. 
 
Acknowledgements 
The authors wish to thank Bryn Beveridge for his expertise and assistance with the 
diagrams, and Dr Bram Piersma for his invaluable assistance with the manuscript.  
 
Figures 
Figure 1.  Mechanisms of Cardiac Dysfunction in Trauma.   
Numbered stages showing sensing of injury by innate immune system, inflammatory 
activation and leukocyte infiltration, upregulation of oxidative stress inducing enzymes 
and finally cell damage, apoptosis and impaired function.   
Figure 2.  The Shifting Balance in Protective Versus Stress Inducing Factors in the 
Heart After Trauma.   
Altering this balance pharmacologically in favour of protective factors has been 
repeatedly shown to prevent myocardial dysfunction and injury following trauma.  
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Table 1.  Synopsis of the Animal Model Data of Secondary Cardiac Injury Following 
Isolated Trauma  
Animal Model  
(& Reference)  
Cardiac 
Monitoring  
Substances 
Measured 
Therapeutic 
Intervention(s) 
Nature of 
Cardiac 
Dysfunction 
Summary of 
Main 
Findings 
Noble Collip 
drum 
(21,22) 
 
Not 
performed  
TNFα  
NO  
Caspase 3  
IL-1  
IFN
iNOS  
NADPH 
Anti-TNFα  
Anti-INOS  
Anti-NADPH 
Not Measured Oxidative, 
nitrative 
stress 
associated 
with TNFα led 
to apoptosis 
Noble Collip 
drum 
(26) 
In-vivo 
arterial 
blood 
pressure via 
transducer  
MPO,  
ICAM-1, 
nitrotyrosine 
 Reduction in 
+dp/dtmax 
and –dp/dt 
max. 
Leukocyte 
infiltration, 
nitrative and 
oxidative 
stress 
Noble Collip 
drum 
(25) 
In-vitro 
Langendorff, 
balloon 
transducer 
in left 
ventricle 
NO 
iNOS 
superoxide 
Caspase 
inhibition 
(Z-VAD-FMK) 
 
Reduction in 
+dp/dtmax 
and –dp/dt 
max. 
Free radicals 
and nitrative 
damage 
linked to 
apoptosis 
Noble Collip 
Drum 
(23) 
Left 
ventricle in-
vivo 
pressure 
transduced  
TNFα  
H202  
PI3K  
Akt 
Insulin Reduction in 
+dp/dtmax 
and –dp/dt 
TNFα, 
reactive oxide 
species led to 
apoptosis 
Noble Collip 
Drum  
(24) 
In-vitro  
Langendorff, 
balloon 
transducer 
in left 
ventricle 
Beclin 
LC3 
Rapamycin 
(promotes 
autophagy) 
Reduction in 
+dp/dtmax 
and –dp/dt 
max.  
Reduction in 
autophagy 
post trauma 
Noble Collip 
drum  
(66) 
In-vivo 
Left 
ventricle 
pressure 
transduced  
Reactive 
oxide species 
TNFα 
apoptotic 
markers 
Quercetin Reduction in 
+dp/dtmax 
and –dp/dt 
max.  
Inflammation 
and ROS 
associated 
with 
apoptosis 
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Table 2.  Synopsis of the Animal Model Data of Secondary Cardiac Injury Following 
Isolated Haemorrhage 
Animal 
Model  
(& 
References)  
Cardiac 
Monitoring  
Substances 
Measured 
Therapeutic 
Intervention(s) 
Nature of 
Cardiac 
Dysfunction 
Summary of 
Main Findings 
Volume 
targeted 
(30% 
circulating 
volume 
venesection 
(58) 
In-vitro 
Langendorff 
method, 
intraventricular 
pressure 
balloon 
TNF  TLR-4  
TNFα knockout 
Reduction in 
+dp/dtmax 
and –dp/dt 
max 
Dysfunction 
linked to TLR4 
and p55 TNFα 
receptor 
MABP of 
50mmhg, 
resuscitated 
with Ringers 
lactate and 
autologous 
transfusion 
(53) 
In-vitro 
Langendorff 
method, 
intraventricular 
pressure 
balloon 
TNFα Prazosin Reduction in 
+dp/dtmax 
and –dp/dt 
max  
Dysfunction 
linked to alpha 
adrenoceptor 
Targeted 
MABP of 
35mmhg, 
resuscitated 
with Ringers 
lactate 
(57) 
None TNFα  
NF-κB  
 
None  Rise in TNFα 
and NF-κB in 
cardiomyocytes 
post HS 
MABP target 
40mmhg, 
reinfusion of 
shed blood 
(62), (65) 
In-vitro 
Langendorff 
method, 
intraventricular 
pressure 
balloon 
TNFα Dipyrimadole 
Lymph drainage 
Reduction in 
+dp/dtmax 
and –dp/dt 
max. 
Reduced 
inflammatory 
cytokines and 
lymph drainage 
associated with 
cardioprotection  
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Table 3.  Summary of the Animal Model Data of Secondary Cardiac Injury Following 
Combined Trauma-Haemorrhage 
Animal Model  
(& References)  
Cardiac 
Monitoring  
Substances 
Measured 
Therapeutic 
Intervention(s) 
Nature of 
Cardiac 
Dysfunction 
Summary of 
Main Findings 
Blood pressure 
target. 
Thoracotomy.  
Non-
resuscitated 
(27-28) 
In-vivo  
Arterial and left 
ventricle 
pressure 
transducer  
NF-κB  
PI3K/Akt  
TNFα 
TLR-9 ligand 
(CPG-ODN1826) 
TLR-4 antagonist 
Reduction in 
SV and 
reduction in 
+dp/dtmax 
and –dp/dt 
max  
TLR-9 ligand led 
to PI3K, 
MEK/ERK 
dependent 
cardioprotection 
MABP target of 
40mmhg and 
maximum bleed 
out. 
Laparotomy.  
Fluid 
resuscitate  
(29-30, 64) 
 
In-vivo  
Left ventricle 
pressure 
transducer.  
P38 MAPK 
eNOS  
Nitrate 
Nitrite 
ICAM-1 
IL-6 
TNF α  
CINC-1 
MIP-2 
MPO 
Akt 
17B estradiol 
Tropisetron 
Hydrogen 
sulphide 
Reduction in 
+dp/dtmax 
and –dp/dt 
max  
Increased 
cytokine levels, 
decrease in 
p38MAPK.  
Akt 
cardioprotective 
limiting 
apoptosis 
Fixed pressure 
shock, MABP 35 
mmhg for 90 
minutes. 
Laparotomy. 
Autologous 
transfusion  
(31-32) 
In-vitro 
Langendorff 
method, 
intraventricular 
pressure 
balloon 
None Lymph duct 
ligation  
Reduction in 
+dp/dtmax 
and –dp/dt 
max.  
Dysfunction 
limited by lymph 
duct ligation  
Laparotomy, 
fixed pressure 
shock model 
and 
resuscitation  
(33-35, 38-39, 
41-45, 47-49, 
69) 
In-vivo 
Indocyanine 
green 
fluorescence 
dilution 
technique and 
left ventricle 
pressure 
transducer  
Estradiol 
Progesterone 
IL-6 
ICAM-1 
MPO  
CINC-1 & 3 
HSPs 
P38,  
Glycogen 
Akt  
TNFα,  
HO-1 
iNOS,  
PI3K Akt, 
Oestrogen 
receptors 
Cyclooxygenase 
Il-6 antibody 
17B estradiol 
Progesterone 
PPAR-gamma 
Diarylpropionitrile 
(beta oestrogen 
agonist) 
Reduction in 
CO, SVR, 
+dp/dtmax 
and –dp/dt 
max 
Cardiac IL-6, NF-
κB, TNFα, ICAM-
1, MPO 
associated with 
neutrophil 
infiltration, 
dysfunction and 
apoptosis  
 
Cardioprotection 
from HSP, PI3K, 
Akt, HO-1, E2 
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Laparotomy, 
fixed pressure 
shock model 
and 
resuscitation.  
(36, 76) 
   
In-vivo  
Left ventricle 
and arterial 
pressure 
transducer. 
Radioactive 
microsphere 
cardiac output 
monitor 
NF-κB  
ICAM-1  
MPO  
Il-6  
CINC-1 & 3 
Glucosamine 
PUGNAc 
Anti IL-6 antibody 
Reduction in 
CO, 
+dp/dtmax 
and –dp/dt 
max 
Rise in cardiac 
NF-κB, IL-6, 
TNFα, ICAM-1, 
MPO associated 
inflammation 
and cardiac 
dysfunction 
Laparotomy, 
fixed pressure. 
Resuscitation  
(78) 
Not performed Il-6 
NF-κB  
HIF-1α  
YC-1  
(anti HIF-1 α) 
 Il-6 rise in 
cardiomyocytes 
induced by HIF-
1α 
  
 
